Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)

1. Peters, S.
2. Gettinger, S.
3. Johnson, M.L.
4. Jänne, P.A.
5. Garassino, M.C.
6. Christoph, D.
7. Toh, C.K.
8. Rizvi, N.A.
9. Chaft, J.E.
10. Costa, E.C.
11. Patel, J.D.
12. Chow, L.Q.M.
13. Koczywas, M.
14. Ho, C.
15. Früh, M.
16. Van Den Heuvel, M.
17. Rothenstein, J.
18. Reck, M.
19. Paz-Ares, L.
20. Shepherd, F.A.
21. Kurata, T.
22. Li, Z.
23. Qiu, J.
24. Kowanetz, M.
25. Mocci, S.
26. Shankar, G.
27. Sandler, A.
28. Felip, E.
29. Mostrar todos los/as autores/as +